After birth, a TSH sample of thyroid function is taken from each newborn to exclude congenital hypothyroidism. When left untreated, congenital hypothyroidism causes severe growth failure and permanent mental retardation. These can be prevented by early hormone replacement therapy. Because it is very difficult to detect the disease in a newborn, all newborns in Finland are screened using a sample of umbilical cord blood.
Neonatal Metabolic Screen (B-VasSeu2)
All newborns will be screened for expanded screening for congenital metabolic diseases at 2 to 5 days of age, subject to parental permission. The screen looks for more than 20 separate metabolic diseases, among others. congenital adrenal hyperplasia (CAH), fatty acid oxidation disorders (MHCAD and LCHAD), glutaric acid type 1 (GA 1) and phenylketonuria (PKU). Early detection of these diseases is important because they are treatable diseases found early, but lead to injury or death if the diagnosis is delayed.
Neonatal Hearing Aid (OAE)
The purpose of the screen is to find children who have hearing problems early enough to start treatment early and ensure the best possible development. If one ear hears, it is enough for social hearing and speech learning.
All newborns are examined for OAE, or oto-acoustic emission from one ear. If the child has hereditary or recurrent hearing defects, OAE in each ear is examined. If the child does not pass the OAE examination in the first ear, it is examined in the second ear. If the child does not pass the OAE examination for both ears, the examination will be re-examined by the maternity ward of the maternity hospital, pediatric ward or midwife at the appropriate time within approximately 2 weeks.
If the child does not pass the OAE hearing on both ears repeatedly and under good conditions, the pediatrician will refer him / her to the Children’s Hearing Board at the latest by 3 months.